Hungary approves China's CanSino coronavirus vaccine for emergency use

Hungary has granted China's CanSino vaccine emergency use authorisation, making it the second China-developed Covid-19 vaccine approved in the European country

Vaccine
Coronavirus vaccines
IANS Budapest
2 min read Last Updated : Mar 24 2021 | 8:26 AM IST

Hungary has granted China's CanSino vaccine emergency use authorisation, making it the second China-developed Covid-19 vaccine approved in the European country, Hungarian Chief Medical Officer Cecilia Muller said.

Apart from the CanSino vaccine, the National Institute of Pharmacy and Nutrition has also approved the import of CoviShield, the Indian version of the AstraZeneca vaccine, Muller told a news conference, Xinhua news agency reported on Tuesday.

"We will search the four corners of the world to have enough vaccines in the country," she said.

The Hungarian government has been enriching its inoculation program with multiple vaccines in the fight against a third wave of the pandemic. So far, it has gained access to vaccines from five producers worldwide, including China's Sinopharm.

The use of Russian and Chinese vaccines has greatly contributed to the acceleration of the Hungarian vaccine program, according to Hungarian Minister of Foreign Affairs and Trade Peter Szijjarto.

"Vaccine is not a question of ideology for us; it is a matter of saving lives. And if we had not contracted Chinese and Russian vaccines, we could not have saved the health and lives of so many Hungarians," the minister said in a recent interview with Russia Today.

Hungary, the first European Union member state to purchase a Chinese vaccine and authorize its use, started to administer the Sinopharm vaccine on February 24.

--IANS

int/

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusHungaryChinaCoronavirus Vaccine

First Published: Mar 24 2021 | 8:16 AM IST

Next Story